Aggression
Return to Library
Research from University of Liverpool has provided new data on cancer therapy
2009 JUL 13 - (NewsRx.com) -- New investigation results, 'Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer,' are detailed in a study published in British Journal of Cancer. According to recent research published in the British Journal of Cancer, "Cytoglobin (Cygb) was first described in 2002 as an intracellular globin of unknown function. We have previously shown the downregulation of cytoglobin as a key event in a familial cancer syndrome of the upper aerodigestive tract." "Cytoglobin expression and promoter methylation were investigated in sporadic head and neck squamous cell carcinoma (HNSCC) using a cross-section of clinical samples. Additionally, the putative mechanisms of Cygb expression in cancer were explored by subjecting HNSCC cell lines to hypoxic culture conditions and 5-aza-2-deoxycitidine treatment. In clinically derived HNSCC samples, CYGB mRNA expression showed a striking correlation with tumor hypoxia (measured by HIF1A mRNA expression p=0.013) and consistent associations with histopathological measures of tumor aggression. CYGB expression also showed a marked negative correlation with promoter methylation (p=0.018). In the HNSCC cell lines cultured under hypoxic conditions, a trend of increasing expression of both CYGB and HIF1A with progressive hypoxia was observed. Treatment with 5-aza-2-deoxycitidine dramatically increased CYGB expression in those cell lines with greater baseline promoter methylation," wrote R.J. Shaw and colleagues, University of Liverpool. The researchers concluded: "We conclude that the CYGB gene is regulated by both promoter methylation and tumor hypoxia in HNSCC and that increased expression of this gene correlates with clincopathological measures of a tumour's biological aggression." Shaw and colleagues published their study in British Journal of Cancer (Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. British Journal of Cancer, 2009;101(1):139-44). For additional information, contact R.J. Shaw, University of Liverpool, Molecular Genetics and Oncology Group, School of Dental Sciences, Liverpool, UK. The publisher's contact information for the British Journal of Cancer is: Nature Publishing Group, 345 Park Avenue South, New York, NY 10010-1707, USA. Keywords: United Kingdom, Liverpool, Cancer Therapy, Familial Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms, Hereditary, Oncology, Squamous Cell Carcinoma, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
